Compare AU

Compare LSGE vs. DRUG

Compare shares and ETFs on the ASX that you can trade on Pearler.

Loomis Sayles Global Equity Fund - Active ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Loomis Sayles Global Equity Fund - Active ETF (LSGE) and the BetaShares Global Healthcare ETF - Currency Hedged (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

LSGE

DRUG

Popularity

Low

Low

Pearlers invested

1

64

Median incremental investment

$290.50

$990.50

Median investment frequency

Fortnightly

Monthly

Median total investment

$0

$1,959.07

Average age group

N/A

26 - 35


Key Summary

LSGE

DRUG

Strategy

LSGE.AX was created on 2021-10-01 by Loomis Sayles. The fund's investment portfolio concentrates primarily on total market equity. To provide a rate of return (after fees and expenses and before taxes) which exceeds the return of the Funds benchmark over a full market cycle.

DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

Top 3 holdings

Meta Platforms Inc Class A (7.32 %)

MercadoLibre Inc (6.69 %)

Amazon.com Inc (5.61 %)

CHF - SWISS FRANC (0 %)

AUD - AUSTRALIA DOLLAR (0 %)

DKK - DANISH KRONE (0 %)

Top 3 industries

Consumer Discretionary (33.65 %)

Communication Services (33.28 %)

Information Technology (26.44 %)

Other (75.53 %)

Communication Services (33.53 %)

Health Care (24.47 %)

Top 3 countries

United States (71.71 %)

Switzerland (8.14 %)

Denmark (6.30 %)

Management fee

0.99 %

0.57 %


Key Summary

LSGE

DRUG

Issuer

Loomis Sayles

BetaShares

Tracking index

MSCI ACWI Index - AUD - Benchmark TR Net

Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD

Asset class

ETF

ETF

Management fee

0.99 %

0.57 %

Price

$3.56

$8.36

Size

$49.795 million

$182.401 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

0.71 %

1.90 %

Market

ASX

ASX

First listed date

30/09/2021

08/08/2016

Purchase fee

$6.50

$6.50


Community Stats

LSGE

DRUG

Popularity

Low

Low

Pearlers invested

1

64

Median incremental investment

$290.50

$990.50

Median investment frequency

Fortnightly

Monthly

Median total investment

$0

$1,959.07

Average age group

N/A

26 - 35


Pros and Cons

LSGE

DRUG

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher price growth

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Higher management fee

  • Lower price growth

  • Lower distribution yield

LSGE

DRUG

Lower exposure to US market

Higher exposure to US market

Higher management fee

Lower management fee

Lower price growth

Higher price growth

Lower distribution yield

Higher distribution yield

Home